🇺🇸 FDA

Intelligence Platform

Patents

Browse 1,444 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 8101584

Method and medicament for inhibiting the expression of a given gene

Alnylam Pharmaceuticals, Inc. · Granted Tue Jan 24 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 19 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8084250

Defensin-antigen fusion proteins

The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Tue Dec 27 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 22 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8084599

Methods and compositions for the specific inhibition of gene expression by double-stranded

INTEGRATED DNA TECHNOLOGIES, INC. · Granted Tue Dec 27 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 22 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8084234

Isolated nucleic acid molecules encoding a fusion protein capable of binding VEGF

REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 27 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 22 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8080532

Compositions and methods for inhibiting expression of Huntingtin gene

Alnylam Pharmaceuticals, Inc. · Granted Tue Dec 20 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 15 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8080651

Juvenile hemochromatosis gene (HFE2A), expression products and uses thereof

Xenon Pharmaceuticals Inc. · Granted Tue Dec 20 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 15 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8080246

Colony stimulating factor 1 receptor (CSF1R) extracellular domain fusion molecules

Five Prime Therapeutics, Inc. · Granted Tue Dec 20 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 15 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8058025

Methods for determining efficacy of chemotherapeutic agents

Precision Therapeutics, Inc. · Granted Tue Nov 15 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8058257

Compositions and methods for inhibiting expression of a gene from the JC virus

Alnylam Pharmaceuticals, Inc. · Granted Tue Nov 15 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8048646

NELL peptide expression systems and bone formation activity of NELL peptide

The Regents of the University of California · Granted Tue Nov 01 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 27 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8030493

Monovalent and divalent salts of N-(5-hydroxynicotinoil) -L-glutamic acid exhibiting psych

Obschestvo S Ogranichennoy Otvetstvennostyu “Natsionalnaya Isseldovatelskaya Kompaniya” · Granted Tue Oct 04 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 29 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8022052

Inhibition of PPAR gamma expression by specific osteogenic oxysterols

The Regents of the University of California · Granted Tue Sep 20 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 15 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8017321

Gefitinib sensitivity-related gene expression and products and methods related thereto

The Regents of the University of Colorado, a Body Corporate · Granted Tue Sep 13 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 08 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8003619

Method of stimulating an immune response and inhibiting expression of a gene using an olig

Alnylam Pharmaceuticals, Inc. · Granted Tue Aug 23 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 18 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7998682

Method for assessing atherosclerosis by measuring expression of FOS or DUSP1 in monocytes

The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Tue Aug 16 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 11 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7994307

RNAi modulation of the BCR-ABL fusion gene and uses thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Aug 09 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 04 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7994309

Compositions and methods for inhibiting expression of a mutant gene

Alnylam Pharmaceuticals, Inc. · Granted Tue Aug 09 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 04 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7985581

Multiple RNA polymerase III promoter expression constructs

Alnylam Pharmaceuticals, Inc. · Granted Tue Jul 26 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 21 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7985887

Regulation of endogenous gene expression in cells using zinc finger proteins

Sangamo Biosciences, Inc. · Granted Tue Jul 26 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 21 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7981610

ZAP-70 expression as a marker for chronic lymphocytic leukemia / small lymphocytic lymphom

The United States of America, as represented by the Department of Health and Human Services · Granted Tue Jul 19 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 14 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7982014

FGFR3-IIIc fusion proteins

Five Prime Therapeutics, Inc. · Granted Tue Jul 19 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 14 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7977457

Fusion proteins, uses thereof and processes for producing same

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Jul 12 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 07 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7972601

Method of promoting delivery of an antioxidant agent to a cell expression neuroligin

The Regents of the University of California · Granted Tue Jul 05 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 30 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7972598

VEGF-binding fusion proteins and therapeutic uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 05 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 30 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted